SFS
CASI

Sowell Financial Services’s CASI Pharmaceuticals CASI Stock Holding History

Sowell Financial Services’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25
Closed – – 860
2021
Q1 		$0 Buy
+25
New +$702 ﹤0.01% 3116

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sowell Financial Services's CASI Position: Q2 2021 in Review

Sowell Financial Services sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 25 shares.

Sowell Financial Services first reported a position in CASI in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • Sowell Financial Services reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 25 CASI Pharmaceuticals shares in Q2 2021.
  • Sowell Financial Services first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Sowell Financial Services's CASI Pharmaceuticals position peaked at $0 in Q1 2021.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.